{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:29:38Z","timestamp":1786408178583,"version":"build-2736575974"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Urology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ajur.2025.11.004","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:55:05Z","timestamp":1777046105000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From molecules to the clinic\u2014pathophysiology of sodium-glucose cotransporter 2 inhibitors and their emerging role in urology: A comprehensive review from the European Association of Urology Section of Endourology"],"prefix":"10.1016","volume":"13","author":[{"given":"Ali","family":"Talyshinskii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-7141","authenticated-orcid":false,"given":"Vineet","family":"Gauhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9956-1558","authenticated-orcid":false,"given":"Steffi","family":"Kar Kei Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcuk","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-0507","authenticated-orcid":false,"given":"Theodoros","family":"Tokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Tsaturyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Enikeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-6478","authenticated-orcid":false,"given":"Bhaskar","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajur.2025.11.004_bib1","first-page":"496","article-title":"Comorbidity burden and health-related quality of life in men with advanced prostate cancer","volume":"31","author":"Benzo","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ajur.2025.11.004_bib2","article-title":"The association of metabolic syndrome and urolithiasis","volume":"2015","author":"Wong","year":"2015","journal-title":"Internet J Endocrinol"},{"key":"10.1016\/j.ajur.2025.11.004_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e41768","article-title":"Risk of poor glycemic control in tamsulosin versus finasteride users with type 2 diabetes mellitus","volume":"11","author":"Nguyen","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.ajur.2025.11.004_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes\u2014global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.ajur.2025.11.004_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on SGLT2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ajur.2025.11.004_bib6","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajur.2025.11.004_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of severe urinary tract infections","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.6002\/ect.IAHNCongress.25","article-title":"A story of serendipities: from phlorizin to gliflozins","volume":"21","author":"Helvac\u0131","year":"2023","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.ajur.2025.11.004_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00592-018-1206-z","article-title":"The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering","volume":"56","author":"J\u00f6rgens","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ajur.2025.11.004_bib10","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.ajur.2025.11.004_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/1947-2714.128471","article-title":"Canagliflozin: a novel SGLT2 inhibitor for type 2 diabetes mellitus","volume":"6","author":"Kaushal","year":"2014","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.ajur.2025.11.004_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2014.03.008","article-title":"Dapagliflozin: glucuretic action and beyond","volume":"82","author":"Balakumar","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ajur.2025.11.004_bib13","article-title":"Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"3","author":"Neumiller","year":"2014","journal-title":"Drugs Context"},{"key":"10.1016\/j.ajur.2025.11.004_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-018-0878-6","article-title":"Ertugliflozin: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ajur.2025.11.004_bib15","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1097\/MS9.0000000000002624","article-title":"Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus","volume":"86","author":"Saleem","year":"2024","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.ajur.2025.11.004_bib16","article-title":"Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ajur.2025.11.004_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40265-014-0204-x","article-title":"Ipragliflozin: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ajur.2025.11.004_bib18","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.3390\/ijms25136926","article-title":"Transporter proteins as therapeutic drug targets\u2014with a focus on SGLT2 inhibitors","volume":"25","author":"Komaniecka","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajur.2025.11.004_bib19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajur.2025.11.004_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfae211","article-title":"Beyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease","volume":"40","author":"Wagner","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ajur.2025.11.004_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/psp4.12498","article-title":"Differentiating the sodium-glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling","volume":"9","author":"Sokolov","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ajur.2025.11.004_bib22","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajur.2025.11.004_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1440-1681.1986.tb00346.x","article-title":"Effect of sodium intake and sodium delivery to the macula densa on renal renin content and juxtaglomerular apparatus morphology","volume":"13","author":"Wong","year":"1986","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ajur.2025.11.004_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1152\/ajprenal.00402.2019","article-title":"Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells","volume":"318","author":"Satou","year":"2020","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ajur.2025.11.004_bib25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000499597","article-title":"Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ajur.2025.11.004_bib26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/JU.0000000000001021","article-title":"Partial nephrectomy for patients with severe chronic kidney disease\u2014is it worthwhile?","volume":"204","author":"Aguilar Palacios","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.11.004_bib27","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.3390\/jcm12196202","article-title":"Role of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease, congestive heart failure and stroke\u2014a review and clinical guide for healthcare professionals","volume":"12","author":"Singh","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib28","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on body weight, BMI, and body composition in adults with type 2 diabetes mellitus: a systematic review","volume":"16","author":"Naeem","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ajur.2025.11.004_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/cer-2019-0002","article-title":"Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in type II diabetes patients","volume":"8","author":"Coleman","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ajur.2025.11.004_bib30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib31","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/dom.13224","article-title":"Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin","volume":"20","author":"Polidori","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.ajur.2025.11.004_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117414","article-title":"Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro","volume":"247","author":"Wei","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.ajur.2025.11.004_bib33","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ehf2.14296","article-title":"Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight","volume":"10","author":"Ghosal","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ajur.2025.11.004_bib34","first-page":"165","article-title":"The obesity epidemic and its impact on urologic care","volume":"17","author":"Mobley","year":"2015","journal-title":"Rev Urol"},{"key":"10.1016\/j.ajur.2025.11.004_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib36","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajur.2025.11.004_bib37","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2147\/DMSO.S258593","article-title":"Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice","volume":"13","author":"Nguyen","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.ajur.2025.11.004_bib38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajur.2025.11.004_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib40","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib41","doi-asserted-by":"crossref","first-page":"JC26","DOI":"10.7326\/J23-0009","article-title":"In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y","volume":"176","author":"Kwong","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib42","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajur.2025.11.004_bib43","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bcp.12104","article-title":"Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease","volume":"76","author":"Cravedi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajur.2025.11.004_bib44","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v16.i2.98552","article-title":"Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort","volume":"16","author":"Lu","year":"2025","journal-title":"World J Diabetes"},{"key":"10.1016\/j.ajur.2025.11.004_bib45","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ajur.2025.11.004_bib46","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3390\/cells12182221","article-title":"Canagliflozin, an inhibitor of the Na+-coupled D-glucose cotransporter, SGLT2, inhibits astrocyte swelling and brain swelling in cerebral ischemia","volume":"12","author":"Shim","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ajur.2025.11.004_bib47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.ajur.2025.11.004_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13057","article-title":"mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging","volume":"19","author":"Van Skike","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.ajur.2025.11.004_bib49","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fphar.2019.00362","article-title":"Canagliflozin inhibits human endothelial cell proliferation and tube formation","volume":"10","author":"Behnammanesh","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajur.2025.11.004_bib50","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","article-title":"Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity","volume":"35","author":"Jenkins","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajur.2025.11.004_bib51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","article-title":"Diabetic vascular diseases: molecular mechanisms and therapeutic strategies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.ajur.2025.11.004_bib52","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajur.2025.11.004_bib53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jdi.13329","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients","volume":"12","author":"Kashiwagi","year":"2021","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.ajur.2025.11.004_bib54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12933-025-02655-2","article-title":"Cellular crosstalk in organotypic vasculature: mechanisms of diabetic cardiorenal complications and SGLT2i responses","volume":"24","author":"Wang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajur.2025.11.004_bib55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5551\/jat.RV17001","article-title":"Role of NLRP3 inflammasomes in atherosclerosis","volume":"24","author":"Karasawa","year":"2017","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.ajur.2025.11.004_bib56","doi-asserted-by":"crossref","first-page":"8162","DOI":"10.3390\/ijms24098162","article-title":"Portrayal of NLRP3 inflammasome in atherosclerosis: current knowledge and therapeutic targets","volume":"24","author":"Tanase","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajur.2025.11.004_bib57","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajur.2025.11.004_bib58","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.juro.2015.12.068","article-title":"The NLRP3 inflammasome mediates inflammation produced by bladder outlet obstruction","volume":"195","author":"Hughes","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.11.004_bib59","article-title":"Role of ROS-induced NLRP3 inflammasome activation in the formation of calcium oxalate nephrolithiasis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajur.2025.11.004_bib60","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41401-022-01031-0","article-title":"SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis","volume":"44","author":"Han","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ajur.2025.11.004_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2438857","article-title":"Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through \u03b2-hydroxybutyrate production","volume":"47","author":"Tian","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.ajur.2025.11.004_bib62","doi-asserted-by":"crossref","first-page":"9481","DOI":"10.3390\/ijms24119481","article-title":"Empagliflozin ameliorates bleomycin-induced pulmonary fibrosis in rats by modulating Sesn2\/AMPK\/Nrf2 signaling and targeting ferroptosis and autophagy","volume":"24","author":"El-Horany","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajur.2025.11.004_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","article-title":"Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway","volume":"195","author":"Lu","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib64","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/ars.2022.0169","article-title":"Dapagliflozin alleviates diabetic kidney disease via hypoxia inducible factor 1\u03b1\/heme oxygenase 1-mediated ferroptosis","volume":"40","author":"Wang","year":"2024","journal-title":"Antioxid Redox"},{"key":"10.1016\/j.ajur.2025.11.004_bib65","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","article-title":"High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection","volume":"8","author":"Umino","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajur.2025.11.004_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ajur.2025.11.004_bib67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.neo.2021.02.003","article-title":"Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin","volume":"23","author":"Papadopoli","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.ajur.2025.11.004_bib68","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1878-0261.13508","article-title":"Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1\u03b1","volume":"17","author":"Biziotis","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ajur.2025.11.004_bib69","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.2217\/nnm-2018-0145","article-title":"Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy","volume":"13","author":"Angelopoulou","year":"2018","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.ajur.2025.11.004_bib70","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jsxm.2018.07.002","article-title":"The favorable effect of empagliflozin on erectile function in an experimental model of type 2 diabetes","volume":"15","author":"Assaly","year":"2018","journal-title":"J Sex Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15217","article-title":"Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: an open-label, non-randomized pilot study","volume":"41","author":"Cannarella","year":"2024","journal-title":"Diabet Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib72","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4274\/cjms.2024.2023-107","article-title":"Revitalizing sexual function in heart failure patients: the impact of sodium-glucose co-transporter 2 inhibitors on erectile dysfunction","volume":"9","author":"Erbay","year":"2024","journal-title":"Cyprus J Med Sci"},{"key":"10.1016\/j.ajur.2025.11.004_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106524","article-title":"Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation","volume":"186","author":"Anan","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ajur.2025.11.004_bib74","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00125-021-05424-4","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis","volume":"64","author":"Kristensen","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajur.2025.11.004_bib75","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1210\/clinem\/dgac154","article-title":"Empagliflozin and decreased risk of nephrolithiasis: a potential new role for SGLT2 inhibition?","volume":"107","author":"Balasubramanian","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajur.2025.11.004_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175993","article-title":"Canagliflozin alleviates experimentally induced benign prostate hyperplasia in a rat model: exploring potential mechanisms involving mir-128b\/EGFR\/EGF and JAK2\/STAT3 signaling pathways through in silico and in vivo investigations","volume":"957","author":"Elbaz","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ajur.2025.11.004_bib77","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3390\/cancers16112145","article-title":"Type disparity in sodium-glucose cotransporter-2 inhibitors in incidences of renal cell carcinoma: a propensity-score-matched cohort study","volume":"16","author":"Lin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajur.2025.11.004_bib78","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/cas.16157","article-title":"Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors","volume":"115","author":"Chiu","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajur.2025.11.004_bib79","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s10557-024-07646-1","article-title":"Associations of SGLT2i with cardiorenal outcomes among diabetics with prostate cancer on hormone therapy","volume":"39","author":"Koutroumpakis","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ajur.2025.11.004_bib80","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","article-title":"The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy","volume":"6","author":"Ali","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.ajur.2025.11.004_bib81","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol Metabol"},{"key":"10.1016\/j.ajur.2025.11.004_bib82","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3390\/jpm11090828","article-title":"The risk of bladder cancer in type 2 diabetes mellitus with combination therapy of SGLT-2 inhibitors and pioglitazone","volume":"11","author":"Li","year":"2021","journal-title":"J Personalized Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib83","first-page":"72","article-title":"A \"golden\" alternative for prevention of cisplatin nephrotoxicity in bladder cancer","volume":"14","author":"Sharon","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ajur.2025.11.004_bib84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00210-018-1564-7","article-title":"Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice","volume":"392","author":"Abdelrahman","year":"2019","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ajur.2025.11.004_bib85","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/dmrr.3797","article-title":"SGLT2 inhibition and three urological cancers: up-to-date results","volume":"40","author":"Lin","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ajur.2025.11.004_bib86","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-017-0611-x","article-title":"Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?","volume":"16","author":"Tanaka","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajur.2025.11.004_bib87","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajur.2025.11.004_bib88","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ajur.2025.11.004_bib90","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/metabo14050264","article-title":"Ketoacidosis and SGLT2 inhibitors: a narrative review","volume":"14","author":"Morace","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.ajur.2025.11.004_bib91","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12894-020-0575-0","article-title":"Diabetic ketoacidosis complicated by emphysematous pyelonephritis: a case report and literature review","volume":"20","author":"Song","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.ajur.2025.11.004_bib92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1297\/cpe.2021-0069","article-title":"Urinary stone in a 12-year-old adolescent with new-onset type 1 diabetes and diabetic ketoacidosis","volume":"31","author":"Ushijima-Fuchino","year":"2022","journal-title":"Clin Pediatr Endocrinol"},{"key":"10.1016\/j.ajur.2025.11.004_bib93","article-title":"Euglycemic diabetic ketoacidosis in a patient with urinary tract infection","volume":"15","author":"Patlolla","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ajur.2025.11.004_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2021.115556","article-title":"Reduction of susceptibility to azoles and 5-fluorocytosine and growth acceleration in Candida albicans in glucosuria","volume":"102","author":"Hiyama","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ajur.2025.11.004_bib96","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00004-22","article-title":"Glycosuria alters uropathogenic Escherichia coli global gene expression and virulence","volume":"7","author":"Islam","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.ajur.2025.11.004_bib97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.ajur.2025.11.004_bib98","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1590\/1806-9282.65.2.246","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review","volume":"65","author":"Figueiredo","year":"2019","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.ajur.2025.11.004_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.910","article-title":"Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: a retrospective cohort study in Korea","volume":"10","author":"Yang","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ajur.2025.11.004_bib100","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologe"},{"key":"10.1016\/j.ajur.2025.11.004_bib101","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s13300-024-01613-7","article-title":"Risk of urogenital bacterial infection with sodium-glucose cotransporter-2 inhibitors: a retrospective cohort study using a claims database","volume":"15","author":"Imai","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ajur.2025.11.004_bib102","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/10600280241312432","article-title":"Sodium-glucose co-transporter 2 inhibitors and severe urinary tract infections: real-world meta-analysis of cohort studies","volume":"59","author":"Aboukaoud","year":"2025","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ajur.2025.11.004_bib103","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajur.2025.11.004_bib104","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.3390\/jcm13216509","article-title":"Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: a multidisciplinary expert consensus","volume":"13","author":"Gorgojo-Mart\u00ednez","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/nep.14167","article-title":"Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries\u2014an expert consensus statement","volume":"28","author":"Liew","year":"2023","journal-title":"Nephrology"},{"key":"10.1016\/j.ajur.2025.11.004_bib106","first-page":"131","article-title":"SGLT2 inhibitor and urinary tract infection in men at risk for voiding dysfunction: a VigiBase analysis","volume":"12","author":"Qian","year":"2025","journal-title":"Urol Pract"},{"key":"10.1016\/j.ajur.2025.11.004_bib107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000539390","article-title":"Emphysematous pyelonephritis in a patient on SGLT2 inhibitor therapy: a rare clinical case report","volume":"14","author":"Artinyan","year":"2024","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.ajur.2025.11.004_bib108","first-page":"163","article-title":"Emphysematous cystitis and urinary retention in a male patient with diabetes mellitus type 2 treated with empagliflozin","volume":"8","author":"Brock","year":"2022","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.ajur.2025.11.004_bib109","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajur.2025.11.004_bib110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.amjcard.2019.10.029","article-title":"Safety of sodium-glucose co-transporter 2 inhibitors","volume":"124","author":"McGill","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ajur.2025.11.004_bib111","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001008772.30001.48.04","article-title":"PD12-04 SGLT2 inhibitors associate with overactive bladder symptoms","volume":"211","author":"Mershon","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.11.004_bib112","article-title":"Effects of switching from another sodium-glucose cotransporter 2 inhibitor to tofogliflozin on nocturia in patients with type 2 diabetes","volume":"16","author":"Inoue","year":"2024","journal-title":"Cureus"}],"container-title":["Asian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388226000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388226000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:41:12Z","timestamp":1786405272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214388226000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2214388226000421"],"URL":"https:\/\/doi.org\/10.1016\/j.ajur.2025.11.004","relation":{},"ISSN":["2214-3882"],"issn-type":[{"value":"2214-3882","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From molecules to the clinic\u2014pathophysiology of sodium-glucose cotransporter 2 inhibitors and their emerging role in urology: A comprehensive review from the European Association of Urology Section of Endourology","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajur.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Editorial Office of Asian Journal of Urology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}